Ot­su­ka puts near­ly $1 bil­lion on the line for four neu­ropsy­chi­atric can­di­dates from Sunovion

It’s been six years since Ot­su­ka got its Lund­beck-part­nered an­tipsy­chot­ic Rex­ul­ti ap­proved to treat schiz­o­phre­nia in the US. Now, the com­pa­ny has its sights set on a new ap­proach for the dif­fi­cult-to-treat dis­ease — and it’s putting down close to $1 bil­lion to snag that can­di­date and three oth­ers from fel­low Japan­ese drug­mak­er Sum­it­o­mo Dainip­pon Phar­ma.

Ot­su­ka is shelling out $270 mil­lion up­front and an­oth­er $620 mil­lion in biobucks for joint de­vel­op­ment and com­mer­cial­iza­tion rights to four neu­ropsy­chi­atric com­pounds from Sum­it­o­mo Dainip­pon’s sub­sidiary Sunovion, the com­pa­nies said on Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.